Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 4
1985 1
1986 1
1987 3
1988 5
1989 8
1990 5
1991 2
1992 1
1993 3
1994 10
1995 8
1996 7
1997 10
1998 13
1999 8
2000 9
2001 7
2002 21
2003 26
2004 28
2005 37
2006 54
2007 50
2008 61
2009 61
2010 73
2011 98
2012 117
2013 149
2014 129
2015 147
2016 151
2017 151
2018 158
2019 157
2020 146
2021 157
2022 165
Text availability
Article attribute
Article type
Publication date

Search Results

2,035 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Zhu FC, et al. Among authors: liu jj. Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702299 Free PMC article. Clinical Trial.
Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity.
Tsuchida CA, Zhang S, Doost MS, Zhao Y, Wang J, O'Brien E, Fang H, Li CP, Li D, Hai ZY, Chuck J, Brötzmann J, Vartoumian A, Burstein D, Chen XW, Nogales E, Doudna JA, Liu JG. Tsuchida CA, et al. Mol Cell. 2022 Mar 17;82(6):1199-1209.e6. doi: 10.1016/j.molcel.2022.02.002. Epub 2022 Feb 25. Mol Cell. 2022. PMID: 35219382 Free PMC article.
2,035 results